Israeli ALS drug shows promise in slowing disease progression

NeuroSense Therapeutics’ Prime, a drug developed in Tel Aviv, demonstrates a 30% slowdown in disease progression in phase 2 trials | Read More in ynet – Culture.   Read More in Israel NOWlej.